Imatikast 400 mg Tablet

Regulated Product — Business License Required

B2B and export product information for licensed and authorized business customers. Contact our team regarding bulk supply, documentation, and applicable commercial, import, and export requirements. This page is not a storefront and no purchasing, checkout, or pricing is offered here.

Product photography not yet supplied — this space will show official packaging imagery once provided by the business.

Product Overview

Imatikast 400 mg Tablet contains imatinib, a tyrosine kinase inhibitor. Its labelling describes it for the treatment of chronic myeloid leukemia and a group of blood diseases in which certain blood cells grow out of control, in adults and children. It is described as blocking the specific abnormal protein that signals cancer cells to multiply, so the cancer cells eventually die.

Active ingredient
Imatinib (as mesylate)
Strength
400 mg
Dosage form
Oral tablet
Therapeutic class
Tyrosine kinase inhibitor (antineoplastic)
Regulatory status
Prescription / regulated — confirmed per enquiry and destination market
Availability
Confirmed per enquiry

Product Information

The following description reflects information associated with this product’s labelling. It has not been independently clinically verified by SDO Pharma and is provided for business and product-identification purposes only. It is not medical advice and does not replace the manufacturer’s official prescribing information.

Described Uses

  • Chronic myeloid leukemia (CML)
  • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL)
  • Myelodysplastic / myeloproliferative diseases (MDS/MPD)
  • Hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL)
  • Dermatofibrosarcoma protuberans (DFSP) and gastrointestinal stromal tumours (GIST)
Note: SDO Pharma has not independently verified the manufacturer’s efficacy claims for this product and makes no additional medical or clinical claims beyond what is described here. We do not claim FDA, UAE, EU, or other specific regulatory approval for this product unless independently verified. This is a prescription / regulated-status product; patient dispensing is the responsibility of the licensed business customer, not SDO Pharma.

Described Dosage & Administration

  • Taken following the doctor’s instructions on dosage and duration
  • Swallowed with a glass of water; the tablet should not be broken, crushed, or chewed
  • Taken with a meal
  • A missed dose is taken soon, but skipped if it is already near the next dose; a double dose should never be taken

Described Side Effects

Commonly described side effects include:

  • Swelling in the face, legs, ankles, and feet
  • Nausea and vomiting
  • Muscle cramps and pain
  • Diarrhoea
  • Skin rash and night sweats
  • Tiredness and dizziness
  • Abdominal pain
  • Increased weight
  • Headache
  • Cough
  • Fever

These are described as commonly temporary. The doctor should be informed if they persist.

Precautions

  • The doctor should be informed of any allergies to the imatinib tablet’s ingredients
  • Before treatment, the doctor should be told about kidney, heart, or liver issues, thyroid problems or thyroid removal, and any history of hepatitis B infection
  • Kept away from children and pets

This summary is provided for informational purposes only and does not replace the manufacturer’s official product labelling or professional medical advice.

B2B, Import & Export

B2B, Import & Export Enquiries

SDO Pharma supports business enquiries for pharmaceutical and healthcare products, including bulk and export supply, subject to applicable licensing, regulatory, import, and export requirements. Requirements vary according to the destination market and the nature of the transaction.

We do not claim that this product is available for import into every country, and we do not claim FDA, UAE, EU, or other specific regulatory approval unless independently verified. Applicable documentation — including a valid Drug License, tax registration, and Importer Exporter Code (IEC) where relevant — is discussed directly with our team as part of the enquiry process. This is a regulated / prescription-status product supplied only to licensed and authorized business customers; SDO Pharma does not sell it directly to individual patients or consumers. See our Regulated Products Policy.

Product Enquiry

Request Product Information

Interested in this product for your business? Submit your enquiry and our team will contact you regarding bulk supply, documentation, and applicable requirements.

Frequently Asked Questions

Per its labelling it contains imatinib and is used for chronic myeloid leukemia and related blood diseases, along with several other conditions, in adults and children. SDO Pharma has not independently verified the manufacturer’s claims and does not claim any specific regulatory approval unless independently confirmed.

Its labelling describes it as swallowed whole with a glass of water, taken with a meal, following the doctor’s instructions on dosage and duration; it should not be broken, crushed, or chewed.

Licensed and authorized business customers can submit the product enquiry form above or contact our team directly. Product availability, documentation, and supply arrangements are confirmed per enquiry.

Availability depends on the destination market’s regulatory requirements and cannot be confirmed without a direct enquiry. See our B2B, Import & Export Enquiries section above.

Explore More

Related Product Categories

SDO Pharma works across several pharmaceutical and healthcare product categories for business customers.

View Products & Services